Certara, Inc. (CERT)
| Market Cap | 942.18M |
| Revenue (ttm) | 418.84M |
| Net Income (ttm) | -1.60M |
| Shares Out | 153.33M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | 13.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,303,713 |
| Open | 6.20 |
| Previous Close | 6.24 |
| Day's Range | 6.12 - 6.28 |
| 52-Week Range | 5.19 - 14.39 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 11.67 (+89.91%) |
| Earnings Date | May 11, 2026 |
About CERT
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scient... [Read more]
Financial Performance
In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $11.67, which is an increase of 89.91% from the latest price.
News
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
Certara Inc. (NASDAQ:CERT) shares are up 2.34% on Wednesday as the company announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business.
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE)...
Veristat to Acquire Certara's Regulatory and Medical Writing Business
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- #Biotech--Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to re...
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first q...
Certara Transcript: Barclays 28th Annual Global Healthcare Conference
Strong 2025 results were driven by disciplined cost management and targeted investments, despite volatility in services and a slowdown in software bookings. New AI-enabled products and cloud offerings are expected to drive growth, while the regulatory writing business is under strategic review.
Certara Transcript: Leerink Global Healthcare Conference 2026
Revenue and EBITDA met expectations, with 2026 growth guided at 0%-4% amid stable markets and strong biosimulation demand. New leadership is driving operational changes, AI integration, and customer-centric strategies, while maintaining disciplined investment and exploring M&A.
Certara Transcript: TD Cowen 46th Annual Health Care Conference
Leadership is focused on operational excellence, innovation, and customer-centric growth, with MIDD and Biosimulation as core drivers. Regulatory services remain under review, while AI integration and cloud migration are set to accelerate growth. Financial guidance anticipates low single-digit growth and stable margins.
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based ph...
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followi...
Certara Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw modest revenue growth, with software outpacing services. 2026 guidance is for flat to low single-digit revenue growth as operational improvements and AI integration are prioritized. Strong cash position and continued R&D investment support long-term growth.
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance
FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth q...
Certara Appoints Jon Resnick as Chief Executive Officer
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth
Certara Transcript: Stephens Annual Investment Conference
Tier 3 biotech demand and biosim services growth offset Tier 1 pharma weakness, while software revenues remain stable and services bookings are more volatile. Regulatory uncertainty and FDA's NAMs directive shape the environment, with AI and cloud adoption driving product innovation, operational efficiency, and future growth.
Certara Transcript: Jefferies London Healthcare Conference 2025
Bookings slowed in Q3, especially among large clients, but biotech demand and backlog remain strong. Strategic product launches, regulatory trends favoring biosimulation, and platform integration are expected to drive growth, with software revenue acceleration targeted for 2026.
Certara Earnings Call Transcript: Q3 2025
Q3 revenue grew 10% year-over-year to $104.6 million, with strong software and QSP performance offset by Tier 1 services softness. 2025 guidance was narrowed, with adjusted EBITDA margin raised to 32% and continued R&D investment. Tier 3 and biotech segments remain resilient.
Certara Reports Third Quarter 2025 Financial Results
RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal ye...
Certara Automates Scientific Workflows with Phoenix® Cloud
RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module...
Certara Expands Biosimulation Market with AI-Driven QSP Platform
RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quanti...
Certara Scientists are Among the Topmost Cited Biopharma Researchers
RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research.
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 afte...
Final Trade: CERT, GDX, IWM, MPC
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Certara Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Certara is accelerating growth through R&D and AI-driven software launches, including Certara IQ for QSP and cloud-based Phoenix. Despite market headwinds, strong adoption of new platforms and a robust FDA relationship support growth. Financially, margins remain stable, with ongoing M&A and a new share buyback program.